Covid-19 Research

Clinical Trials

Effect of Hyperthermic Intraperitoneal Chemotherapy on Long Term Survival in Gastric Cancer with Peritoneal Metastasis Treated With Preoperative Intraperttoneal Chemotherapy plus Peritonectomy: The Phase III PM-GC-1 Trial

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Clinical Trials
Subject Medicine Group
OCLC JBRES Record
Yutaka Yonemura*, Haruaki Ishibashi, Takuji Fujita, Yang Liu, Satoshi Wakama, Syouzou Sako, Toshiyuki Kitai, Yasuo Hirono, Shouzou Sako, Akiyoshi Mizumoto, Sachio Fushida, Nobuyuki Takao, Keizou Taniguchi and Daisuke Fujimoto
Issue: Volume5-Issue7
Pages: 710-717
Received: 2024-06-13
Accepted: 2024-07-03
Published: 2024-07-08

Abstract

The presentation aims to describe the theory for Comprehensive Treatment (COMPT) in order to achieve cure of Colorectal Cancer (CRC)-patients with Peritoneal Metastasis (PM). Comprehensive Treatment (COMPT) consists of complete resection of macroscopic PM and eradication of residual MicroM metastasis (MM) by Intraoperative Hyperthermic Intraperitoneal Chemoperfuion (IOHIPEC). There are four scenarios for cure following COMPT. Scenario A involves cases without MM, where patients will be cured by Cytoreductive Surgery (CRS) alone. Similarly, if the residual number of MM is below than the threshold level that can be completely eliminated by IOHIPEC, patients will be cured (Scenario C). If NAC reduces the MM burden below the threshold level, patients may then be cured by CRS combined with IOHIPEC (Scenario D). If NAC completely eliminates MM, patients will then be cured by CRS alone (Scenario F). Cure is defined as patients survive without recurrence longer than five years after COMPT. The number of cured patients cured were 27/304 (8.9%). Among 304 CRC-patients with PM, ten patients were treated with CRS alone, and one patient with PCI of 4 was cured (Scenario A). Seventy-three patients were treated with CRS plus neoadjuvant chemotherapy (NAC), and 4 (5.5%) were cured (Scenario F).Fifteen patients were treated with CRS plus IOHIPEC, and 3 (20.0%) were cured (Scenario C) 206 patients were treated with NAC plus CRS plus IOHIPEC, and 19 (9.2%) patients were cured (Scenario D). When the patients with PCI less than 4, these patients have a chance of cure by complete removal of PM (CCR-0). CRC-patients with PCI ≤ 12 can be cured by NAC plus CCR-0 CRS plus IOHIPEC. When the patients treated using NAC are considered able to undergo complete, CRS, CRS and intraoperative HIPEC are recommended.

FullText HTML FullText PDF DOI: 10.37871/jbres1946 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2024 Yonemura Y, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Yonemura Y, Ishibashi H, Fujita T, Liu Y, Wakama S, Sako S, Kitai T, Hirono Y, Sako S, Mizumoto A, Fushida S, Takao N, Taniguchi K, Fujimoto D. Effect of Hyperthermic Intraperitoneal Chemotherapy on Long Term Survival in Gastric Cancer with Peritoneal Metastasis Treated With Preoperative Intraperttoneal Chemotherapy plus Peritonectomy: The Phase III PM-GC-1 Trial. J Biomed Res Environ Sci. 2024 Jul 08; 5(7): 710-717. doi: 10.37871/jbres1946, Article ID: JBRES1946, Available at: https://www.jelsciences.com/ articles/jbres1946.pdf

Subject area(s)

Clinical TrialsCancerGastroenterology

References

  1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000 Jan 15;88(2):358-63. doi: 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o. PMID: 10640968.
  2. Sugarbaker PH. Building on a consensus. J Surg Oncol. 2008;98(4):215-216.
  3. Yonemura Y, Canbay E, Endou Y, Ishibashi H, Mizumoto A, Miura M, Li Y, Liu Y, Takeshita K, Ichinose M, Takao N, Hirano M, Sako S, Tsukiyama G. Peritoneal cancer treatment. Expert Opin Pharmacother. 2014 Apr;15(5):623-36. doi: 10.1517/14656566.2014.879571. PMID: 24617975.
  4. Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg. 2005 Mar;92(3):370-5. doi: 10.1002/bjs.4695. PMID: 15739249.
  5. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005 Feb 8;2(1):3. doi: 10.1186/1477-7800-2-3. PMID: 15701175; PMCID: PMC549516.
  6. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Mar 2;19(3):329-359. doi: 10.6004/jnccn.2021.0012. PMID: 33724754.
  7. Colorectal Cancer. NCCN Guidelines Version 2, 2021.
  8. Kusamura S, Kepenekian V, Villeneuve L, Lurvink RJ, Govaerts K, De Hingh IHJT, Moran BJ, Van der Speeten K, Deraco M, Glehen O; PSOGI. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021 Jan;47(1):36-59. doi: 10.1016/j.ejso.2020.02.011. Epub 2020 Mar 12. PMID: 32209311.
  9. Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, Goere D, Baratti D, Nizri E, Morris DL, Glehen O, Sardi A, Barrios P, Quénet F, Villeneuve L, Gómez-Portilla A, de Hingh I, Ceelen W, Pelz JOW, Piso P, González-Moreno S, Van Der Speeten K, Deraco M; Peritoneal Surface Oncology Group International (PSOGI) and the French National Registry of Rare Peritoneal Surface Malignancies (RENAPE). The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. JAMA Surg. 2021 Mar 1;156(3):e206363. doi: 10.1001/jamasurg.2020.6363. Epub 2021 Mar 10. PMID: 33502455; PMCID: PMC7841579.
  10. Terashima M, Fujitani K, Yang HK, Mizusawa J, Tsujinaka T, Nakamura K, Katayama H, Lee HJ, Lee JH, An JY, Takagane A, Park YK, Choi SH, Song KY, Ito S, Park DJ, Jin SH, Boku N, Yoshikawa T, Sasako M; REGATTA study investigators. Role of reduction gastrectomy in patients with gastric cancer with a single non-curable factor: Supplementary analysis of REGATTA trial. Ann Gastroenterol Surg. 2023 Apr 16;7(5):741-749. doi: 10.1002/ags3.12674. PMID: 37663970; PMCID: PMC10472355.
  11. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):787-800. doi: 10.1016/0360-3016(84)90379-1. PMID: 6547421.
  12. Yonemura Y, Ishibashi H, Mizumoto A. A comprehensive treatment to achieve cure for peritoneal metastasis. Taiwanese J Gastroenterol Hepatol. 2023;1(1):1-6,
  13. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011 Jun;18(6):1575-81. doi: 10.1245/s10434-011-1631-5. Epub 2011 Mar 23. PMID: 21431408; PMCID: PMC3087875.
  14. Rau B, Lang H, Koenigsrainer A, Gockel I, Rau HG, Seeliger H, Lerchenmueller C, Reim D, Wahba R, Angele M, Heeg S, Keck T, Weimann A, Topp S, Piso P, Brandl A, Schuele S, Jo P, Pratschke J, Wegel S, Rehders A, Moosmann N, Gaedcke J, Heinemann V, Trips E, Loeffler M, Schlag PM, Thuss-Patience P. Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial. J Clin Oncol. 2024 Jan 10;42(2):146-156. doi: 10.1200/JCO.22.02867. Epub 2023 Oct 31. PMID: 37906724; PMCID: PMC10824373.
  15. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015 May;22(5):1570-5. doi: 10.1245/s10434-014-4157-9. Epub 2014 Nov 13. PMID: 25391263.
  16. Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y, Matsuda M, Yonemura Y, Baba H. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009 Aug;250(2):242-6. doi: 10.1097/SLA.0b013e3181b0c80e. PMID: 19638909.
  17. Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol. 2001 Apr;27(3):239-43. doi: 10.1053/ejso.2000.1038. PMID: 11373099.
  18. Brandl A, Yonemura Y, Glehen O, Sugarbaker P, Rau B. Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI. Eur J Surg Oncol. 2021 Jan;47(1):172-180. doi: 10.1016/j.ejso.2020.10.006. Epub 2020 Oct 14. PMID: 33071173.
  19. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2. PMID: 19638912.
  20. Nagata H, Ishihara S, Hata K, Murono K, Kaneko M, Yasuda K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Watanabe T. Survival and Prognostic Factors for Metachronous Peritoneal Metastasis in Patients with Colon Cancer. Ann Surg Oncol. 2017 May;24(5):1269-1280. doi: 10.1245/s10434-016-5732-z. Epub 2016 Dec 19. PMID: 27995451.
  21. Hong SH, Shin YR, Roh SY, Jeon EK, Song KY, Park CH, Jeon HM, Hong YS. Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer. 2013 Jul;16(3):290-300. doi: 10.1007/s10120-012-0182-1. Epub 2012 Aug 17. PMID: 22898806.
  22. Prabhu A, Mishra D, Brandl A, Yonemura Y. Gastric Cancer With Peritoneal Metastasis-A Comprehensive Review of Current Intraperitoneal Treatment Modalities. Front Oncol. 2022 May 26;12:864647. doi: 10.3389/fonc.2022.864647. PMID: 35719946; PMCID: PMC9204320.
  23. Prabhu A, Brandl A, Wakama S, Sako S, Ishibashi H, Mizumoto A, Takao N, Noguchi K, Motoi S, Ichinose M, Liu Y, Yonemura Y. Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei-A Novel Treatment Approach. Cancers (Basel). 2020 Aug 7;12(8):2212. doi: 10.3390/cancers12082212. PMID: 32784670; PMCID: PMC7465601.
  24. Yonemura Y, Ishibashi H, Hirano M, Mizumoto A, Takeshita K, Noguchi K, Takao N, Ichinose M, Liu Y, Li Y. Effects of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Neoadjuvant Intraperitoneal/Systemic Chemotherapy on Peritoneal Metastases from Gastric Cancer. Ann Surg Oncol. 2017 Feb;24(2):478-485. doi: 10.1245/s10434-016-5487-6. Epub 2016 Aug 9. PMID: 27506661.
  25. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618. PMID: 29342393.
  26. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, Juzyna B, de Forges H, Paineau J, Glehen O; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18. PMID: 33476595.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership